Heart Failure
Conditions
Interventions
Shexiang Baoxin Pill group :two pills of SBP (Shanghai Hutchison Pharmaceuticals, 22.5 mg/pill) each time, three times a day
placebo group :two pills of placebo(Shanghai Hutchison Pharmaceuticals, 22.5 mg/pill) each time, three times a day
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) age>=18 years old, <=75 years old, gender unlimited; 2) confirmed as chronic heart failure according to the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure; 3) HFrEF was confirmed by cardiac ultrasound, and the NYHA cardiac function grade was between grade II~III 4) the subjects voluntarily participated in this study and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients with acute myocardial infarction (within 3 months), acute heart failure, and recent unstable angina pectoris; 2) Individuals who have recently used drugs that affect immune responses, such as corticosteroids. 3) Recent inflammatory reactions such as fever, redness, swelling, pain, rash and other acute and chronic infectious diseases; 4) Patients with combined left ventricular outflow tract obstruction; 5) Combined myocarditis; 6) Uncontrolled severe arrhythmia; 7) Combined aortic aneurysm; 8) Merge severe liver, kidney, hematological, psychiatric or systemic diseases; 9) Significant liver and kidney dysfunction (ALT>2.0 times the upper limit of normal value; blood creatinine>1.5 times the upper limit of normal value); 10) Serum potassium>5.5mmol/L; 11) Uncontrolled hypertension (above 180/110mmHg); 12) Pregnant or lactating women; 13) Allergic to Shexiang Baoxin Pill; 14) Participate in clinical studies of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum free fatty acid;Left ventricular end diastolic volume;Left ventricular end systolic volume;Left ventricular ejection fraction;Left ventricular ejection time;left ventricular stroke volume;myocardial energy expenditure; | — |
Secondary
| Measure | Time frame |
|---|---|
| N-terminal precursor of brain natriuretic peptide;Major Adverse Cardiovascular Events;Arrhythmia; | — |
Countries
China
Contacts
Public ContactPei Nie
Anqing Municipal Hospital
Outcome results
None listed